Target ValidationApril 2026
CD74 Emerges as Biomarker in ALS Cerebrospinal Fluid — Strengthening the Case for JFIN-0001's Second Indication
A multi-center proteomics study published in Nature Neuroscience identifies soluble CD74 fragments as a robust biomarker in ALS patient cerebrospinal fluid, correlating with disease progression and microglial activation state.
JFInnova Perspective
This independently validates JFIN-0001's second indication. Our Digital Twin already models CD74-driven microglial activation in ALS motor cortex — the same target, the same pathway, now with clinical biomarker evidence from a top-tier journal.
CD74 ALS biomarker cerebrospinal fluid